Key terms
About INSM
Insmed, Inc. is a global biopharmaceutical company, which engages in the development and commercialization of therapies for patients with rare diseases. Its focuses on Brensocatib, and Treprostinil Palmitil Inhalation Powder (TPIP) pipeline. The company was founded in 1988 and is headquartered in Bridgewater, NJ.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest INSM news
Apr 16
1:20pm ET
Analysts Offer Insights on Healthcare Companies: Insmed (INSM) and UnitedHealth (UNH)
Apr 01
6:43am ET
Insmed added to ‘Q2 Tactical Ideas List’ at Wells Fargo
Apr 01
6:03am ET
Analysts Are Bullish on Top Healthcare Stocks: Annexon Biosciences (ANNX), Insmed (INSM)
Mar 19
2:08am ET
Strong Endorsement and Market Expansion Potential Justify Buy Rating for Insmed’s Brensocatib
Mar 12
8:20am ET
Analysts Conflicted on These Healthcare Names: Insmed (INSM), Oric Pharmaceuticals (ORIC) and CytomX Therapeutics (CTMX)
Mar 07
7:30am ET
Analysts Offer Insights on Healthcare Companies: Insmed (INSM) and Zimmer Biomet Holdings (ZBH)
Mar 05
10:25am ET
Cantor Fitzgerald biotech/biopharma analysts analyst/industry conference call
Mar 05
7:40am ET
Analysts Offer Insights on Healthcare Companies: Incyte (INCY) and Insmed (INSM)
Mar 05
4:55am ET
Cantor Fitzgerald biotech/biopharma analysts analyst/industry conference call
Mar 01
12:19pm ET
Cantor Fitzgerald biotech/biopharma analysts analyst/industry conference call
Feb 28
12:06am ET
Buy Rating Affirmed for Insmed on Positive Pipeline Prospects and Robust Revenue Forecasts
Feb 27
8:35am ET
Insmed price target raised to $54 from $52 at Guggenheim
Feb 26
4:26pm ET
Insmed initiated with a Buy at UBS
Feb 26
1:26am ET
3 Best Stocks to Buy Now, 2/26/2024, According to Top Analysts
Feb 25
11:26pm ET
Buy Rating Affirmed for Insmed on Strong Sales and Promising Trial Outlook
Feb 23
7:46am ET
Buy Recommendation for Insmed: Underestimated Drug Potential and Solid Financials
Feb 23
6:48am ET
Insmed price target raised to $40 from $37 at BofA
Feb 23
6:20am ET
Wall Street Analysts Are Bullish on Top Healthcare Picks
Feb 23
3:16am ET
Barclays Sticks to Its Buy Rating for Insmed (INSM)
Feb 22
10:50pm ET
Analysts Offer Insights on Healthcare Companies: Insmed (INSM) and BioMarin Pharmaceutical (BMRN)
Feb 22
8:16am ET
Insmed Strikes $500M Deal with Leerink for Growth and R&D
Feb 22
7:04am ET
Insmed reports Q4 EPS ($1.28), consensus ($1.15)
Feb 15
6:40am ET
Analysts’ Opinions Are Mixed on These Healthcare Stocks: American Well (AMWL), Biogen (BIIB) and Insmed (INSM)
Feb 15
1:37am ET
Buy Rating Affirmed for Insmed Amid Competitor Setbacks and Promising Market Expansion Opportunities
Feb 14
7:26pm ET
Insmed initiated with an Outperform at Wolfe Research
Feb 14
4:15pm ET
Insmed initiated with an Outperform at Wolfe Research
Feb 13
5:11am ET
Optimistic Outlook for Insmed’s Brensocatib Program: Reaffirming Buy Rating Ahead of ASPEN Trial Results
Feb 13
5:04am ET
Buy Recommendation for Insmed Amid Reduced Competition and Promising Upcoming Trial Readouts
Feb 01
8:00am ET
Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX), Insmed (INSM) and Amgen (AMGN)
No recent press releases are available for INSM
INSM Financials
Key terms
Ad Feedback
INSM Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
INSM Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
